Last updated: 2026-09-23 11:51:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
SL Science Holding Limited (SLBT) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1,75, with a market capitalization of $964,51M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,66 to $14,50. This page covers its latest market performance, valuation, price trends and company information.
$964,51M | |
$1,75 | |
$53,95 | |
$1,66 | |
$1,68 | |
79,00 | |
122,39K | |
-- | |
$14,50 | |
$1,66 | |
-- | |
-- |
SL Science Holding Limited (SLBT) is trading at $1,75 in pre-market trading as of 2026-09-23 08:04:00, up 4,17% ($0,07) from the previous close of $1,68
Pre-market trading shows how investors are pricing SLBT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, SL Science Holding Limited (SLBT) moved from $2,07 to $1,75, representing a decline of 15,46% ($0,32).
The stock traded between $1,66 and $2,18 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 99,38 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,7%
SLBT is currently trading at $1,75, placing it 0,7% of the way from its 52-week low of $1,66 to its 52-week high of $14,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SL Science Holding Limited (SLBT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.